Oncolytics Biotech Inc ONCY

Primary Symbol: T.ONC

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > Clinical Trial Size in Orphan and Rare Diseases

<< Previous

Bullboard Posts

Next >>

Comment by Noteableon Sep 25, 2024 6:18pm

98 Views

Post# 36241150

RE:RE:RE:RE:RE:Clinical Trial Size in Orphan and Rare Diseases

Presented November 9, 2023 at the 2nd International Multidisciplinary Anal Cancer Conference (IMACC)

Study Design & Treatment Regimen:

Open-label, single arm, Simon Two-stage study of pelareorep + atezolizumab (n=10)

Enrollment Expanded:

Ongoing • Stage 1 success criteria met; Stage 2 enrollment (18 patients) ongoing

Combined results could lead to a single-arm registration study

https://oncolyticsbiotech.com/wp-content/uploads/2024/09/Oncolytics_Deck-Sept_2024-v4.pdf

<< Previous

Bullboard Posts

Next >>

AI companies to invest in